Display options
Cite
Sheffield BS, Bosdet IE, Ali RH, et al. Relationship of thyroid transcription factor 1 to EGFR status in non-small-cell lung cancer. Curr Oncol. 2014;21(6):305-8doi: 10.3747/co.21.2148.
Sheffield, B. S., Bosdet, I. E., Ali, R. H., Young, S. S., McNeil, B. K., Wong, C., Dastur, K., Karsan, A., & Ionescu, D. N. (2014). Relationship of thyroid transcription factor 1 to EGFR status in non-small-cell lung cancer. Current oncology (Toronto, Ont.), 21(6), 305-8. https://doi.org/10.3747/co.21.2148
Sheffield, B S, et al. "Relationship of thyroid transcription factor 1 to EGFR status in non-small-cell lung cancer." Current oncology (Toronto, Ont.) vol. 21,6 (2014): 305-8. doi: https://doi.org/10.3747/co.21.2148
Sheffield BS, Bosdet IE, Ali RH, Young SS, McNeil BK, Wong C, Dastur K, Karsan A, Ionescu DN. Relationship of thyroid transcription factor 1 to EGFR status in non-small-cell lung cancer. Curr Oncol. 2014 Dec;21(6):305-8. doi: 10.3747/co.21.2148. PMID: 25489257; PMCID: PMC4257113.
Copy Download .nbib Format: NLM
Share it on

Curr Oncol. 2014 Dec;21(6):305-8. doi: 10.3747/co.21.2148.

Relationship of thyroid transcription factor 1 to EGFR status in non-small-cell lung cancer.

Current oncology (Toronto, Ont.)

B S Sheffield, I E Bosdet, R H Ali, S S Young, B K McNeil, C Wong, K Dastur, A Karsan, D N Ionescu

Affiliations

  1. Department of Pathology and Laboratory Medicine, BC Cancer Agency. Vancouver, BC.
  2. Pathology Department, Faculty of Medicine and Health Sciences Centre, Kuwait University, Kuwait.

PMID: 25489257 PMCID: PMC4257113 DOI: 10.3747/co.21.2148

Abstract

BACKGROUND: Activating mutations of the epidermal growth factor receptor (EGFR) gene are known to drive a proportion of non-small-cell lung cancers. Identification of lung cancers harbouring such mutations can lead to effective treatment using one of the agents that targets and blocks egfr-mediated signalling.

METHODS: All specimens received at the BC Cancer Agency (Vancouver) for EGFR testing were prospectively identified and catalogued, together with clinical information and EGFR status, over a 14-month period.

RESULTS: Specimens from 586 patients were received for EGFR testing, and EGFR status was reported for 509 patients. No relationship between specimen type or site of origin and EGFR test failure rate was identified. Concurrent immunohistochemical (ihc) status for thyroid transcription factor 1 (ttf1) was available for 309 patients. The negative predictive value of ttf1-negative status by ihc was 94.2% for predicting negative EGFR status.

CONCLUSIONS: In patients with limited tissue available for testing, a surrogate for EGFR status would aid in timely management. Immunohistochemistry for ttf1 is readily available and correlates highly with EGFR status. In conjunction with genetic assays, ttf1 could be used to optimize an EGFR testing strategy.

Keywords: EGFR; adenocarcinoma; biomarker testing; lung cancer; non-small-cell lung cancer; nsclc; thyroid transcription factor 1; ttf1

References

  1. Clin Cancer Res. 2005 Feb 1;11(3):1167-73 - PubMed
  2. N Engl J Med. 2010 Jun 24;362(25):2380-8 - PubMed
  3. Ann Oncol. 2006 Nov;17(11):1673-6 - PubMed
  4. Nat Rev Cancer. 2007 Mar;7(3):169-81 - PubMed
  5. Arch Pathol Lab Med. 2013 Jun;137(6):828-60 - PubMed
  6. J Thorac Oncol. 2012 Oct;7(10):1522-7 - PubMed
  7. N Engl J Med. 2008 Mar 13;358(11):1160-74 - PubMed
  8. N Engl J Med. 2013 Jun 20;368(25):2385-94 - PubMed
  9. J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 - PubMed
  10. Curr Oncol. 2012 Apr;19(2):e67-74 - PubMed
  11. PLoS One. 2014 Apr 17;9(4):e95479 - PubMed
  12. Nature. 2007 Dec 6;450(7171):893-8 - PubMed
  13. J Mol Diagn. 2005 Aug;7(3):396-403 - PubMed
  14. J Thorac Dis. 2013 Oct;5 Suppl 5:S479-90 - PubMed
  15. Cancer. 2007 Feb 15;109(4):741-50 - PubMed

Publication Types